PBA
PHVS icon

Paradigm Biocapital Advisors’s Pharvaris PHVS Stock Holding History

Paradigm Biocapital Advisors’s Portfolio PHVS Stock Details PHVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,835,494
Closed -$45.8M – 42
2025
Q3 		$45.8M Buy
1,835,494
+772,583
+73% +$17.1M 1.3% 22
2025
Q2 		$18.7M Buy
+1,062,911
New +$17.1M 0.8% 25

Other funds holding PHVS

GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
EFM
EQT Fund Management Luxembourg $1.02B AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Paradigm Biocapital Advisors's PHVS Position: Q4 2025 in Review

Paradigm Biocapital Advisors sold out of Pharvaris (PHVS) in Q4 2025, closing a stake of 1,835,494 shares — an estimated $45.8M sold.

Paradigm Biocapital Advisors first reported a position in PHVS in Q2 2025 and held it in 2 quarters. The position peaked at $45.8M in Q3 2025. 106 funds tracked by Wall St. Rank hold PHVS as of Q4 2025.

  • Paradigm Biocapital Advisors reported no remaining Pharvaris position as of Q4 2025 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 1,835,494 Pharvaris shares in Q4 2025, an estimated $45.8M.
  • Paradigm Biocapital Advisors first reported a position in Pharvaris in Q2 2025 and held it in 2 quarters.
  • Paradigm Biocapital Advisors's Pharvaris position peaked at $45.8M in Q3 2025.
  • 106 funds tracked by Wall St. Rank held Pharvaris as of Q4 2025.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.